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1. Introduction 
Cancer of the kidney comprises approximately 3% of all cancers in males and 2% in females 
according to Cancer Research UK statistics. (http://info.cancerresearchuk.org) Similar 
figures are seen globally. The majority (around 90%) of kidney cancers are Renal Cell 
Carcinomas (RCC), and clear cell carcinomas (adenocarcinomas) are the most common 
histological subtype. (Cohen & McGovern, 2005) The remaining 20-25% are papillary (Type I 
and II) (10-15%), chromophobe (4%) and collecting duct (including the rare medullary 
variant) (<1%) RCCs. (Cohen & McGovern, 2005) Up to a third of patients present at initial 
diagnosis with evidence of distant metastases, and a third of patients who undergo 
nephrectomy will have a recurrence within 5 years. These patients are considered 
candidates for systemic therapy. (Molina & Motzer, 2008) 
2. Molecular pathogenesis 
2.1 Clear-cell variant renal cell carcinoma 
Unravelling of the biology, genetics and intracellular molecular signalling pathways of RCC 
has greatly improved our understanding of this disease. (Tan et al, 2010) The discovery of 
von Hippel-Lindau (VHL) tumour suppressor gene as a critical oncogene in the 
pathogenesis of renal cell carcinoma (clear-cell as well as some of the non-clear-cell variant) 
has greatly revolutionised the systemic therapy for renal-cell carcinoma where previously 
treatment had been disheartening. (Choueiri et al, 2008; Cohen & McGovern, 2005) The VHL 
protein (pVHL) encoded by the VHL tumour suppressor gene serves to regulate the normal 
cellular response to oxygen deprivation through its interaction with hypoxia-inducible 
factor (HIF). HIF is a heterodimeric (HIF-ǂ/ǃ) gene transcription factor that consists of an 
unstable ǂ-subunit and a stable ǃ-subunit. In the presence of normal oxygen tension (or 
normoxic state), VHL protein is the substrate recognition of an E3 ubiquitin ligase complex 
that targets HIF-ǂ subunits for destruction by the proteasome as illustrated in Figure 1. 
(Kamura et al, 2000; Ohh et al, 2000) In the absence of functional VHL proteins, either as a 
result of mutation or hyper-methylation of the VHL gene as seen in majority of sporadic 
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cases of RCC (equivalent to a physiological hypoxic state), the pVHL-HIF-ǂ interaction is 
disrupted due to loss of oxygen-dependent hydroxylation of HIF-ǂ subunits leading to their 
intracellular accumulation. (Maxwell et al, 1999) HIF-ǂ subunits are able to then translocate 
into the nucleus where they heterodimerize with the HIF-ǃ subunits forming transcriptional 
factor complexes that induce transcription of various hypoxia-response genes. (Amato, 2011) 
This in turn leads to the increased production of downstream pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and 
transforming growth factor alpha and beta (TGF-ǂ and TGF-ǃ) as illustrated by Figure 1.  
(Kim & Kaelin, 2004) It is noteworthy that angiogenesis holds the key to tumour survival 
when the rapidly growing tumour outstrips its own existing blood supply. It utilized the 
effective HIF mechanism to promote its own survival, growth and progression (metastasis). 
(Vaupel, 2004)  
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Fig. 1. (a) Normoxia/normal VHL gene (b) Hypoxia/inactivated tumour suppressor VHL 
gene 
2.2 Non clear-cell variant renal cell carcinoma 
Papillary RCC is the second most common histological subtype of the non-clear cell variant 
of RCC. (Cohen & McGovern, 2005) It can be further categorized histologically into papillary 
types I and II with emerging data suggesting an underlying different genetics and molecular 
pathways. (Furge et al, 2010) Papillary type I RCC is associated with activating mutations of 
methyl-nitroso-nitroguanidine-induced (MET) oncogene. (Choi et al, 2006; Dharmawardana 
et al, 2004) These mutations results in ligand-independent activation of intracytoplasmic 
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tyrosine kinase domains which subsequently activate the hepatocyte growth factor/MET 
pathway. (Choi et al, 2006; Sudarshan & Linehan, 2006) Papillary type II RCC, in contrast is 
attributed to mutation of the fumarate hydratase (FH) tumour suppressor gene. (Linehan et 
al, 2007) FH is a tricarboxylic acid (Kreb) cycle enzyme that has a crucial role in aerobic 
cellular metabolism. (Isaacs et al, 2005) Mutation of FH (inactivation) leads to the generation 
of a pseudo-hypoxic state with subsequent upregulation of the HIF-ǂ subunits. The mutated 
FH enzyme allows the accumulation of fumarate which in turn leads to inhibition of HIF-
prolyl hydroxylase (HPH), a critical enzymatic regulator of intracellular HIF-ǂ. When HPH 
is inactivated, the hydroxylation of HIF is disrupted leading to failure of recognition by 
pVHL; thus preventing the VHL-dependent proteosomal degradation of HIFs. 
Accumulation of HIF-ǂ leads to downstream transcriptional overexpression of pro-
angiogenic factors as described in the previous section. (Isaacs et al, 2005) 
Chromophobe RCC accounts for 4% of all RCC. (Cohen & McGovern, 2005) Whilst the exact 
mechanism underlying its pathogenesis is not well established, the VEGF-angiogenic 
pathway was again implicated in view of the elevated levels of VEGF and its receptor 
mRNA in this variant of RCC. The KIT oncogene and the folliculin (FLCN) gene associated 
with the hereditary form of chromophobe/oncocytic RCC hybrid (Birt-Hogg-Dubé 
Syndrome) are other molecular targets identified in this variant. (Pavlovich et al, 2002; 
Yamazaki et al, 2003; Zbar et al, 2002) Due to the rarity of collecting duct RCC (including the 
virulent medullary variant), the underlying pathogenesis has not been identify. (Oudard et 
al, 2007a) 
3. Prognostic indicators  
For patients with recurrent or metastatic disease, a question often faced by the treating 
physician is their prognosis as treatment is being contemplated. In metastatic RCC, 
numerous studies have been undertaken to investigate the prognostic markers for metastatic 
RCC. (Tan et al, 2010) Five prognostic markers linked to the overall survival rate of patients 
with metastatic RCC have been identified. These include performance status, absence or 
presence of prior nephrectomy, serum lactate dehydrogenase, corrected serum calcium and 
haemoglobin level. (Motzer et al, 1999) Based on these criteria, patients could be grouped 
into three prognostic risk categories: favourable (0 risk features), intermediate (1-2 risk 
features) and poor (≥3 risk features) according to the Memorial Sloan-Kettering Cancer 
Centre (MSKCC) risk classification. (Motzer et al, 1999) Previous radiotherapy, time to 
systemic therapy, and the presence of hepatic, pulmonary, and retroperitoneal nodal 
metastasis were found to be independent prognostic factors in later studies. (Mekhail et al, 
2005) The stratification of the different prognostic factors of renal carcinoma in clinical 
studies is important to allow comparison of therapies and to gain insight into the cohort of 
patients that would most benefit from the investigational agent.  
When comparing with the clear-cell variant of RCC, localized papillary RCC when 
resectable, has a more favourable prognosis than conventional clear cell. (Cheville et al, 2003; 
Patard et al, 2005) However, metastatic papillary RCC portends a worse prognosis than their 
clear-cell counterpart. (Margulis et al, 2008) The type II papillary variant is thought to be 
more aggressive than type I with a higher propensity to metastasize early and progress 
rapidly. (Motzer et al, 2004)  Chromophobe RCC is considered a good prognostic variant 
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and is associated with earlier stage tumour and longer overall survival compared to clear-
cell RCC. In the metastatic setting, the reports from the medical literature are however 
conflicting. (Beck et al, 2004; Cindolo et al, 2005; Klatte et al, 2008; Motzer et al, 2002) 
Collecting duct RCC is associated with a grave prognosis, with up to one-third of patients 
presenting with metastatic disease on initial presentation. (Motzer et al, 2002) 
4. Systemic treatment of metastatic renal cell carcinoma 
Metastatic RCC is inherently refractory to chemotherapy and hormonal therapies. (Harris, 
1983; Yagoda & Bander, 1989)  The response rate of these treatment options are in the order 
of 10% thereby rendering RCC notoriously difficult to treat. (Yagoda & Bander, 1989)  
Solitary metastatic lesions may be surgically resected however beyond surgery, the only 
systemic options available prior to the era of targeted therapy were interferon alpha (IFN-ǂ) 
and interleukin 2 (IL-2). (Oudard et al, 2007b) Allogeneic stem cell transplantation to induce 
a graft-versus-tumour response has also been examined but at the expense of significant life-
threatening toxicities. This is therefore not recommended outside a clinical trial setting. 
(Barkholt et al, 2006; Gommersall et al, 2004; Rini et al, 2002) Patients with good prognostic 
features had a response rate of 10-20% to IFN-ǂ and IL-2 and a modest improvement of 
median survival by ~2.5 months with IFN-ǂ. (1999; Coppin et al, 2005) High dose IL-2 
(infusion therapy requiring hospitalization) conferred a durable but small long term disease 
remission of ~5% in clinical responders. (Fyfe et al, 1995; McDermott et al, 2005) Both 
cytokine treatments especially with high dose IL-2 are toxic and difficult to administer. The 
classical side-effects of flu-like syndrome, depression with suicidal episodes from IFN-ǂ; 
(Cohen & McGovern, 2005; Motzer et al, 1996) hypotension, oliguria, capillary-leak 
syndrome with secondary multi-organ failure, somnolence and confusion from IL-2 would 
render both treatments very onerous to patients. (Cohen & McGovern, 2005; Parton et al, 
2006) Moreover the reported mortality rate of 4% from IL-2 would dilute any modest 
survival advantage gained. (Fyfe et al, 1995) Not surprisingly, the underlying enthusiasm in 
utilizing these agents as frontline therapy in metastatic RCC has been dampened with the 
advent of targeted therapies. 
4.1 VEGF ligands and receptor inhibitors 
Vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and other 
angiogenic ligands once produced are able to circulate freely to to interact with cell surface 
receptors on the endothelial cell. Upon binding of these ligands to their cognate receptors, a 
cascade of intracellular signalling takes place resulting in downstream activation of Raf and 
mitogen-activated protein kinase (MAPK) (via phospholipase C-Ǆ). This ultimately leads to 
the promotion of tumour angiogenesis, endothelial cell survival, proliferation, and 
migration. (Cebe-Suarez et al, 2006) The discovery of these complex VEGF signalling 
pathways presented an opportunity as therapeutic targets to treat metastatic RCC. VEGF 
signaling blockade can be achieved by either the removal of the circulating ligand with 
monoclonal antibody (bevacizumab) or by inhibiting its receptors with tyrosine kinase 
inhibitors (TKIs) as illustrated by Figure 1. (Jonasch et al, 2011) The four anti-VEGF 
therapies approved as of 2011: sunitinib, sorafenib, pazopanib and bevacizumab have 
revolutionized the treatment of metastatic RCC leading to significant improvement in 
progression-free survival (PFS) and in some instances overall survival (OS). (Tan et al, 2010)  
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4.1.1 Sunitinib 
Sunitinib is an oral multi-kinase inhibitor that targets several VEGF receptors (VEGF-1, 
VEGF-2, VEGF-3) and other tyrosine kinase receptors (PDGFR, c-Kit, FLT-3, CSF-1R, and 
RET). (Abrams et al, 2003; Kim et al, 2006; Mendel et al, 2003; Murray et al, 2003; O'Farrell et 
al, 2003) Earlier uncontrolled trials showed sunitinib to be active in patients with advanced 
malignancies including RCC. (Faivre et al, 2006) 
4.1.1.1 Sunitinib Intermittent Dosing (4 Weeks On / 2 Weeks Off) 
The initial phase II study of sunitinib in patients with cytokine-refractory metastatic renal 
cell cancer assessed the clinical efficacy and safety of sunitinib as second-line therapy. 
(Motzer et al, 2006) The sixty three patients who failed cytokine-based therapy received 
50mg of sunitinib for 4 weeks followed by a 2 week break (4/2), in a 6 week cycle. Forty 
percent (n=25) of patients had partial response (PR) and 27% (n=17) additional patients 
demonstrated stable disease (SD) for ≥3 months. The median time to progression and 
survival were 8.7 months and 16.4 months respectively. (Motzer et al, 2006)   
A larger phase II multicentre trial similarly confirmed the anti-cancer efficacy of sunitinib in 
cytokine refractory patients with metastatic RCC. One hundred and six patients were 
enrolled and an overall objective response (ORR) of 44% was noted with 1% (n=1) and 43% 
(n=45) demonstrating a CR and PR respectively. (Motzer et al, 2007b) An additional 22% 
(n=23) showed SD for ≥ 3 months. The median duration of response for the 46 responding 
patients was 10 months whilst the median progression free survival (PFS) was 8.3 months. 
(Motzer et al, 2007b) 
As the ORR of sunitinib seen in phase II trials far exceeded the rates previously reported for 
cytokine therapy as first line treatment of metastatic disease (42% vs. 10–15%), an 
international landmark phase III trial comparing sunitinib with INF-ǂ for patients with 
metastatic clear-cell RCC was undertaken. (Costa & Drabkin, 2007; Motzer et al, 2007a)  
Seven hundred and fifty treatment naϊve patients with clear-cell histology and good 
performance status (ECOG 0 or 1) were randomized in a 1:1 ratio to receive either sunitinib 
(dose as per earlier studies) or INF-ǂ (9 × 106 units subcutaneously thrice weekly). (Desai et 
al, 2007; Motzer et al, 2007a) The median duration of treatment was 6 months (1-15 months) 
in the sunitinib group and 4 months (1-13 months) in the IFN-ǂ group. The median PFS  
assessed by an independent third-party review was 11 months in the sunitinib group and 5 
months in the IFN-ǂ group, corresponding to a Hazard Ratio (HR) of 0.42 (95% CI 0.32–0.54; 
p < 0.001). (Motzer et al, 2007a) The investigators’ assessment showed similar results, with a 
PFS of 11 months in the sunitinib and 4 months in the IFN-ǂ group. An updated analysis 
published in 2009 has shown the ORR of 47% for sunitinib and 12% for IFN-ǂ (p< 0.000001), 
with a median PFS of 11 months and 5 months, respectively, for sunitinib and IFN-ǂ 
(p< 0.000001), similar to the original report. (Motzer et al, 2009) These results were uniformly 
seen, regardless of patient’s age, gender and prognostic category.  (Motzer et al, 2009) 
Patients on sunitinib also experienced a median OS in excess of 2 years. The OS was 
26.4 months for sunitinib and 21.8 months for IFN-ǂ (p = 0.051).  (Motzer et al, 2009) A 
separate exploratory analysis of patients on both treatment arms who did not receive post-
study cancer treatment showed the median OS with sunitinib was twice as long as IFN-ǂ 
(28.1 months versus 14.1 months respectively, p=0.003). (Motzer et al, 2009) Based on these 
positive results, sunitinib has replaced INF-ǂ in the first line treatment of metastatic RCC. 
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In addition to the aforesaid clinical trials, sunitinib was also evaluated in an expanded-
access programme, designed to allow access to sunitinib in patients with metastatic RCC 
who would otherwise be excluded from the clinical trials. (Gore et al, 2009) Over 4500 
patients, including older patients (≥65 years-old; n=1414), those with poorer performance 
status (ECOG PS ≥2; n=582), non-clear cell histology (n=288) and with brain metastases 
(n=320) were enrolled in this international, open-label study, thus resembling a more “real-
world” setting. (Gore et al, 2009) Patients received a median of five sunitinib treatment 
cycles, with 56% of patients receiving more than 6 months of sunitinib therapy for a median 
duration of 15.6 months. In the total evaluable study population (n=4349), the median PFS 
was 10.9 months and median OS was 18.4 months. (Gore et al, 2009) The median PFS closely 
resembles the phase III study demonstrating consistent efficacy across patients within and 
outside clinical trials. No differences were noted in median PFS and OS between patients 
with or without prior cytokine therapy. Subgroup analysis of elderly patients demonstrated 
median PFS and OS of 11.3 and 18.2 months respectively. (Gore et al, 2009) In patients with 
poorer performance status, median PFS and OS were 5.1 months and 6.7 months 
respectively and lastly in patients with brain metastases with an overall poorer prognosis, a 
median PFS of 5.6 months and median OS of 9.2 months were observed. (Gore et al, 2009) 
4.1.1.2 Sunitinib Continuous Dosing 
Sunitinib has also been examined in an open-label multicentre phase II trial using 
continuous once daily dosing at a dose of 37.5 mg. (Escudier et al, 2009b) One hundred and 
seven patients were randomised equally to either morning or evening dose for a median 8.3 
months. Forty three percent of patients had dose reduction to 25mg due to grade 3-4 adverse 
effects. (Escudier et al, 2009b) The ORR was 20%, with a median duration of response of 7.2 
months, median PFS of 8.2 months and OS of 19.8 months. (Escudier et al, 2009b) The 
tolerability of the morning and evening dosing as well as the reporting quality of life (QoL) 
whilst on therapy was similar. Grade 3 diarrhoea, fatigue/asthenia and hand-foot syndrome 
were however noted more in the evening dosing cohort. This continuous regimen appeared 
promising and certainly deserves further investigation as this dosing schedule may benefit 
patients who are not able to tolerate the intermittent sunitinib dosing of 50mg and where 
one is concerned that the intermittent 37.5mg is suboptimal.  
Sunitinib standard dosing schedule (50mg/day; 4 weeks on, 2 weeks off) was compared 
with continuous dose (37.5 mg/day) in a phase II trial (EFFECT) for patients with locally 
recurrent clear-cell RCC or metastatic RCC who had received no previous systemic therapy 
for advanced disease. The intermittent schedule when compared with the continuous 
schedule showed a trend to improved ORR (32.2% vs. 28.1%; p=0.444) and median PFS (8.5 
months vs. 7.0 months; p=0.070). No difference were noted between the median OS (23.1 
months vs. 23.5 months, p=0.615). (Motzer et al, 2011b) Interestingly the median OS was 
lower than the phase III sunitinib vs. INF-ǂ trial which had a median OS of 26 months. The 
phase III trial had a higher number of patients with better baseline prognostic features 
(better performance status and more patients had underwent nephrectomy) which may 
account for better survival results. (Motzer et al, 2011b; Motzer et al, 2007a) 
4.1.2 Sorafenib 
Sorafenib is an oral multi-kinase inhibitor that inhibits Raf (Raf-1, B-Raf, and mutant b-raf 
V600E), VEGF (VEGF-2, VEGF-3), PDGFR (PDGFR-ǂ, PDGFR-ǃ), c-KIT, FLT3 and RET. 
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(Carlomango 2006, Wilhelm 2004) A phase II randomized discontinuation trial in 202 
patients with metastatic RCC who failed previous systemic treatments were treated with 
sorafenib at 400 mg BD. (Ratain et al, 2006) Seventy-three patients exhibited tumour 
shrinkage of more than 25%. Sixty-five patients with stable disease at 12 weeks were 
randomly assigned to sorafenib (n=32) or placebo (n=33). Patients on sorafenib experienced 
prolonged median PFS (24 weeks) when compared to placebo (6 weeks) (p = 0.087). (Ratain 
et al, 2006) A second phase II trial comparing sorafenib with INF-ǂ as first line treatment 
was undertaken in treatment naϊve patients with metastatic RCC. Patients were randomised 
to receive sorafenib 400mg BD or IFN-ǂ (9 million units thrice weekly). There was an option 
of dose escalation to sorafenib 600mg BD or crossover from INF-ǂ to sorafenib upon disease 
progression. There was no significant improvement in PFS of sorafenib vs. placebo, 5.7 
months vs. 5.8 months respectively. The ORR was 5% with sorafenib and 9% with IFN-ǂ. 
(Escudier et al, 2009c) 
A subsequent multi-centre placebo controlled phase III trial (TARGET) randomised 903 
patients with metastatic clear-cell RCC on 1:1 to receive either placebo or sorafenib 400mg 
BD. The study cohort consisted of patients who previously received cytokine therapies with 
IFN-ǂ, IL-2 or a combination of both, or radiotherapy, or had a nephrectomy. After 
3 months of therapy, sorafenib resulted in a higher ORR (57% vs. 34%) and statistically 
significant longer PFS (5.5 months vs. 2.8 months; p< 0.001 with a HR of 0.44) when 
compared with placebo. (Escudier et al, 2007b) This was consistent with an earlier phase II 
second line trial that found PFS benefit was independent of age over or under 70 years, 
prognostic risk, prior cytokine therapy, lung, liver, bone or brain metastases, time from 
diagnosis, or whether or not the patient had clinical cardiovascular disease. (Beck et al, 2011; 
Escudier et al, 2007b) The latter included patients with ischemic heart disease, a previous 
myocardial infarction, left ventricular dysfunction, hypertension, epistaxis or central 
nervous system ischemia. (Beck et al, 2011) Patients on the placebo arm were permitted to 
cross over to sorafenib on diagnosis of progressive disease. In the first interim analysis, a 
trend towards better OS was noted in patients taking sorafenib, and this was unchanged in 
the final analysis (17.8 vs. 15.2 months, respectively, HR= 0.88; p = 0.146). (Escudier et al, 
2007b; Escudier et al, 2009a) However, after placebo patients who crossed over on 
progression were censored, the difference in OS became significant (17.8 vs. 14.3 months; 
HR = 0.78; p = 0.029). (Escudier et al, 2007b)  
Sorafenib has also been evaluated in two open-label expanded access studies in Europe (The 
European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCS) and North America 
ARCCS (NA-ARCCS). The NA-ARCCCS offered insights into sorafenib in the real world 
setting. (Beck et al, 2008; Beck et al, 2011; Stadler et al, 2010)  In Europe, about 1155 patients 
who failed at least one line of systemic therapy or were unsuitable for cytokine therapy 
received sorafenib 400mg BD until treatment intolerance or disease progression. Interim 
analysis revealed a median PFS of 6.9 months (95% CI: 6.2 – 7.5 months). (Beck et al, 2008) 
The North American access study enrolled 2515 patients in total with 2504 patients having 
received at least one cycle of sorafenib and therefore evaluable. Patients who had received 
no prior systemic therapy were allowed enrolment. Except for the difference in the median 
time from diagnosis (0.6 years vs. 2.2 years), prior nephrectomy rates (77% vs. 89%) and the 
incidence of >2 sites of metastatic disease prior to study entry (30% vs. 38%), the baseline 
characteristics were mostly balanced for patients who were treatment-naïve and patients 
who had at least one prior systemic treatment. The rate of disease progression was similar 
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for fist-line sorafenib patients and patients who had received at least on e prior systemic 
treatment (16% vs. 17%). Similarly the rates of PFS and disease control (ORR + stable 
disease) were 83% vs. 84% in the first-line and prior systemic therapy cohorts, respectively. 
(Eisenhauer et al, 2009) These results demonstrate that sorafenib provides similar benefit in 
first- and second- or later line patient populations in a non-randomised, open access trial. 
(Stadler et al, 2010) 
4.1.3 Pazopanib 
Pazopanib is an oral multi-targeted receptor tyrosine kinase inhibitor that inhibits VEGF 
(VEGF-1, VEGF-2, VEGF-3), PDGF (PDGF-ǂ, PDGF-ǃ) and c-KIT. (Hutson et al, 2010) 
Pazopanib showed activity in a phase I trial with 2 partial responders and 4 patients 
achieving disease stability out of a total 12 patients. (Hurwitz et al, 2009) Subsequently, a 
randomised phase II study to determine the ORR, duration of response and PFS was 
undertaken on patients with predominantly clear-cell histology who had never been treated 
or had failed one line of non-multi-kinase therapy. This study was originally designed as a 
randomized discontinuation study but revised to an open-label study after a planned 
interim analysis undertaken at 12 weeks showed a response rate of 38%. (Hutson et al, 2010) 
This was confirmed to be similar on an independent review. The final analysis of this trial 
showed an ORR (CR  + PR) of 33.8%  with similar response rate between the treatment naϊve 
cohort (34%; 95% CI 26% to 41%) and patients with one previous line of therapy (37%; 95% 
CI 26% to 49%). The median duration of response was 68 weeks. The estimated median PFS 
was 11.9 months for pazopanib vs. 6.2 months for placebo. (Rini & Al-Marrawi, 2011)  
Pazopanib was subsequently tested in a phase III trial where a total of 233 treatment-naïve 
and 202 cytokine-pretreated patients with advanced clear-cell RCC were randomized in a 
2:1 ratio to pazopanib (n = 290) or placebo (n = 145). (Sternberg et al, 2010) Placebo with best 
supportive care was thought to be an acceptable comparator arm due to the inaccessibility 
of other tyrosine kinase inhibitors (sunitinib or sorafenib) in some centres at the time of 
study initiation. Moreover, utilizing placebo control in a randomised double blind design 
enabled better characterization of the safety and efficacy of the profile of pazopanib. Placebo 
with best supportive care remained as the comparator arm as cytokines as the standard of 
care were challenged due to their underlying toxicities. The PFS in the pazopanib arm 
compared with placebo was significantly prolonged in the overall study population 
(9.2 months vs. 4.2 months, HR 0.46; p < 0.0001), in treatment naïve patients (11.1 months vs. 
2.8 months, HR: 0.40, p < 0.001) and in cytokine-pretreated patients (7.4 months vs. 
4.2 months; HR 0.54, p < 0.001). The response rate was 30% with pazopanib versus 3% in the 
placebo group and the median duration of response was 58.7 weeks. The final OS results 
were updated at the European Society of Medical Oncology meeting in 2010. A median OS 
of 22.9 vs. 20.5 months were noted in the pazopanib and placebo arms respectively 
(p=0.224). The lack of significant benefit was attributed to the early, high rate and prolonged 
duration of cross-over from placebo to pazopanib. In fact, more placebo than pazopanib 
patients received subsequent treatment (66% vs. 30% respectively) with 54% of patients on 
placebo crossing over to the active arm, some occurred as early as week 6 into therapy. (Rini 
& Al-Marrawi, 2011; Sternberg, 2010) The efficacy of pazopanib as first line therapy is 
comparable and is an alternative agent in patients who do not tolerate sunitinib. As yet, no 
head-to-head efficacy data are available to show superiority or non-inferiority between 
www.intechopen.com
 
New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma 
 
377 
pazopanib and sunitinib and phase III trial (COMPARZ) is currently underway. 
(NCT00720941, 2011) 
4.1.4 Bevacizumab 
Bevacizumab is a humanized monoclonal antibody that uniquely targets the VEGF molecule 
and thus inhibiting this ligand with all of the receptors to which it binds. (Gommersall et al, 
2004) A randomized phase II trial randomized 116 patients with metastatic clear-cell RCC to 
either placebo, low-dose (3 mg/kg given fortnightly) or high-dose bevacizumab (10 mg/kg 
given fortnightly). Accrual was halted when an interim analysis revealed a time to disease 
progression (TTP) benefit in the (high-dose) bevacizumab arm. A significant prolongation of 
TTP was observed in the high dose bevacizumab group (p<0.001; HR 2.55) compared to the 
placebo, and a smaller TTP benefit of borderline significance was reported for those 
receiving low-dose bevacizumab (p=0.053; HR 1.26). An objective partial response rate of 
10.3% in the high-dose bevacizumab arm was noted. (Yang et al, 2003) Further data of 
bevacizumab as monotherapy was derived from a study comparing bevacizumab 
(10mg/kg; fortnightly) with placebo and bevacizumab with erlotinib (150mg bd), a small-
molecule epidermal growth factor receptor (EGFR) inhibitor. Whilst the combination arm 
was well tolerated, it failed to demonstrate the superiority of this combination over 
bevacizumab alone. (Bukowski et al, 2007b) In both trials, the vast majority of patients 
treated with bevacizumab demonstrated some degree of tumour shrinkage, although in 
most instances the extent of tumour shrinkage did not meet the Response Evaluation 
Criteria in Solid Tumour (RECIST) criteria for PR. Interestingly the efficacy data from these 
two trials suggest the presence of clinical activity of bevacizumab monotherapy for 
metastatic RCC. (Elaraj et al, 2004) This is in clear contrast with other tumour types (non-
small cell lung cancer, metastatic colorectal carcinoma, and metastatic breast carcinoma) 
where clinical benefit of single-agent bevacizumab without accompanying chemotherapy 
has been limited. (McDermott & George, 2010) 
Two parallel large multicentre randomized international trials both examined the clinical 
efficacy of bevacizumab and IFN-ǂ versus IFN-ǂ alone, the previous standard of care for 
systemic treatment of patients with metastatic RCC. (Escudier et al, 2007c; Rini et al, 2008) 
Both trial (AVOREN, n=649; CALGB 90206 Intergroup Study, n=732), randomized 
treatment-naϊve patients to IFN-ǂ (9 × 106 units thrice weekly) and bevacizumab (10 mg/kg 
fortnightly) or placebo and IFN-ǂ. The only difference was that the AVOREN study was 
placebo-controlled and the CALBG 90206 Intergroup study was an open labelled trial. 
(McDermott & George, 2010) 
In the AVOREN study, the ORR was higher in the bevacizumab arm (31.4% vs. 12,8%, 
p=0.0001) with 70% of this group of patients demonstrating tumour shrinkage compared to 
39% of patients on the IFN- ǂ  and placebo arm. The median PFS after a median follow-up of 
22 months demonstrated a better median survival in the bevacizumab arm (10.2 months vs. 
5.5 months; p = 0.0001). The improvement in  PFS was evident irrespective of age, tumour 
subtype (clear cell or mixed), baseline VEGF level, and creatinine clearance. When stratified 
according to the MSKCC criteria, significant PFS benefits are seen in the low- and 
intermediate-risk groups but not detected in the poor risk category. As the number of 
patients enrolled in this poor subgroup were small (<10% of the enrolled patient), it is 
difficult to undertake any meaningful interpretation. (Escudier et al, 2007c) 
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A subsequent unplanned retrospective analysis revealed that PFS benefits was similar in 
39% (n=131) of bevacizumab patients who received either 6 X 106 IU or 3 X 106 IU instead of 
9 X 106 IU due to treatment related toxicity. The ORR for the reduced-dose group and full-
dose group were 34% vs. 31% respectively and median duration of tumour response in turn 
was 13.6 months vs. 13.5 months respectively. This suggested that the dose of IFN-ǂ could 
be reduced without compromising efficacy in patients who could not treatment related 
toxicities of IFN-ǂ. (Melichar et al, 2008) 
At the time of final OS analysis, only a trend towards OS was seen (23 months vs. 
21.3 months, p = 0.1291). The effects of crossover to the bevacizumab arm, as well as the 
availability of second-line therapies where at least 35% received the TKIs (sunitinib and 
sorafenib) in both treatment arms, could well have compounded the results. An exploratory 
analysis showed that median OS was longer in patients receiving subsequent TKI therapy 
after bevacizumab plus IFN-ǂ (n=113) compared with patients receiving TKIs after IFN plus 
placebo (n = 120) 38.6 months vs. 33.6 months respectively. (Escudier et al, 2007a)  
In the Intergroup CALBG 90206, the ORR for active arm versus the control arm was 25.5% 
vs. 13.1% (p<0.0001) and the median PFS was in turn 8.4 months vs. 4.9 months (p<0.0001) 
respectively. (Rini et al, 2008) Only a trend in improved median OS was noted (18.3 months 
vs. 17.4 months, p = 0.097) and the trial did not achieve its primary end point, OS. The HR 
for progression was 0.71, which overlap with the AVOREN trial.  
Stratification by MSKCC risk factors revealed the median PFS to be 11.1 months vs. 5.7 
months in patients with absent risk factors (26%), 8.4 months vs. 5.3 months in patients with 
one or two risk factors (64%), and 3.3 months vs. 2.6 months in patients with three or more 
risk factors (10%), for the bevacizumab combination and INF-ǂ monotherapy treatment 
groups, respectively. When stratified by the MKSCC risk factors, the median OS for 
bevacizumab / INF-ǂ respectively was 32.5 months vs. 33.5 months for the favourable-risk 
group (26% of patients, p=0.524); 17.7 months vs. 16.1 months for the intermediate-risk 
group (64% of patients, p = 0.174) and lastly 6.6 months vs. 5.7 months for the poor risk 
group (p =0.25). (McDermott & George 2011, Rini et al, 2010)  
Whilst no cross-over was allowed for the IFN-ǂ monotherapy arm, 56% of study patients 
proceeded to at least one subsequent further systemic therapy in the form of a TKI. The 
patients who received second-line therapy were subsequently analysed and showed a 
median OS of 31.4 months vs. 26.8 months (p=0.079) in the bevacizumab/IFN-ǂ and IFN-ǂ 
monotherapy arms respectively. Amongst the patients who did not, the survival duration 
were 13.1 months vs. 9.1 months (p=0.059) respectively. (Rini et al, 2010) 
Both trials were statistically robust and showed clear benefits in the median PFS arms with 
an overlapping HR and doubling of PFS when comparing the placebo/IFN-ǂ arm with 
bevacizumab/IFN-ǂ arm. (McDermott & George, 2010) The effects of crossover to the active 
bevacizumab arm in the AVOREN trial, as well as the permission of second-line therapies in 
both trials would account for the dilution of the actual overall survival benefits in both 
trials. (McDermott & George, 2010) Despite the lack of overall survival benefit and the 
notable toxicity of IFN-ǂ with a large percentage of patients in the phase III trials 
undertaking dose reduction (40 – 60%), the combination of bevacizumab and IFN- ǂ 
received Food and Drug Administration (FDA) approval for use as frontline of metastatic 
RCC.  
www.intechopen.com
 
New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma 
 
379 
4.2 mTOR Inhibitors 
The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that plays a crucial 
role in angiogenesis and regulation of cell cycle through a series of complex tightly 
regulated pathways. (Amato, 2011) mTOR activity is affected by a host of factors that 
influence cell functioning including nutrients (glucose, amino acid), energy depletion, as 
well as external signals such as cytokines, hormones, and growth factors. It also reacts to 
cellular stresses such as hypoxia, heat shock, oxidative stress, DNA damage and lastly a 
change in the microenvironment (pH or osmostic cell pressure). (Amato, 2011) The key 
pathway is via the phsophotidylinositol 3 kinase-protein kinase (P13K – AKT) pathway 
which is dysregulated in many cancers. (Amato, 2011; Beuvink et al, 2005) Activation of 
mTOR leads to phosphorylation of down-stream substrates (4E-binding protein-1 and 
protein S6 kinase) which in turn promotes mRNA translation, stimulation of protein 
synthesis and entry into the G1 phase of cell cycle as illuastrated in figure 2. (Beuvink et al, 
2005) Another important role of mTOR is the encoding and subsequent production of HIF-
1ǂ which drives angiogenesis, growth and survival of the cancer cells. The selective 
inhibition of this complex pathway by the mTOR inhibitors is achieved by binding to the 
intracellular protein FK506 binding protein 12 (FKBP-12) and causing inhibition of the 
kinase activity of the mTOR. (Amato, 2011) The two mTOR inhibitors, registered for the 
treatment of metastatic RCC are temsirolimus and everolimus. 
4.2.1 Temsirolimus 
The mTor inhibitor temsirolimus is similar to sirolimus (rapamycin) which has been used as 
an immunosuppressant in renal transplantation for many years. (Hudes et al, 2007) It affects 
cell division by inhibition of mTOR dependent protein translation, via binding to an 
intracellular protein (FK506 Binding Protein 12; FKBP12) resulting in a protein-drug 
complex. Temsirolimus is administered as a weekly intravenous infusion at 25mg. It is 
metabolised by CYP3A4 to active metabolite sirolimus and has a half-life of about 9 to 27 
hours. (Hudes et al, 2007) 
It was approved in 2007 by FDA as a first-line therapy in treatment-naïve metastatic RCC 
with poor prognostic features. Phase I and II trials of temsirolimus alone, or combined with 
IFN-ǂ, found anti-tumour effects and stable disease in patients refractory to cytokine 
therapies. (Hidalgo et al, 2006; Raymond et al, 2004) In addition to that, another phase II trial 
on heavily pre-treated patients observed a median survival of 15 months. (Atkins et al, 2004) 
These encouraging results subsequently  led to the development of an international 
multicentre phase III trial where 626 treatment-naïve patients with poor prognostic factors 
were randomized to temsirolimus (25 mg i.v. weekly), IFN-ǂ (3 × 106 units, with an increase 
to 18 × 106 units s.c. thrice weekly) or the combination of temsirolimus (15 mg weekly) and 
IFN-ǂ (6 × 106 thrice weekly). (Atkins et al, 2004) This was a pivotal trial that enrolled 
patients with poor prognostic factors only unlike previous studies with VEGF inhibitors 
which only recruited patients with good and intermediate risk features. The poor prognostic 
patients consisted of at least three or more of the 6 poor MSKCC prognostic factors. Another 
notable characteristic of recruitment is the enrolment of up to 20% of non-clear cell renal cell 
histological subtype. This is the only randomised study available so far for patients with the 
non-clear cell histology. (Atkins et al, 2004) 
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Fig. 2. External stimuli (growth factors) 
Patients who received temsirolimus alone experienced a longer median OS (10.9 vs. 
7.3 months; p = 0.008) and PFS (3.8 vs. 1.9 months; p < 0.001) compared with those who 
received INF-ǂ alone. (Hudes et al, 2007) Patients in the combination therapy group had the 
most grade 3 or 4 adverse events leading to more dose reductions or delays. Their mean 
temsirolimus dose intensity was 10.9 mg per week vs. 23.1 mg per week for patients on 
temsirolimus alone. The median PFS in the temsirolimus, temsirolimus and IFN-ǂ and IFN-ǂ 
alone were 3.8, 3.7 and 1.9 months, respectively, and the median OS in turn was 10.9 months, 
8.4 months and 7.3 months. (Hudes et al, 2007) Notably, older patients and patients with a 
higher serum LDH (> 1.5 fold the upper limit of normal) had better OS. (Hudes et al, 2007) 
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Clinicians are now faced with the challenge of treating patients who are refractory to VEGF 
targeted therapy as there is paucity of data in this area. The only published prospective 
randomised trial looking at this cohort of patients was RECORD-1 looking at everolimus vs. 
placebo. (Motzer et al, 2008) The few abstracts published on second line treatment with 
temsirolimus are all single institution case series confirming a modest activity in the second 
line setting with a median PFS of up to almost 4 months. 
4.2.2 Everolimus 
Everolimus is a derivative of rapamycin used in transplant medicine. Everolimus is an 
orally administered mTOR inhibitor with activity in patients with advanced clear-cell RCC 
who have failed VEGF-targeted therapies (sorafenib, sunitinib or both). (Motzer et al, 2008) 
Everolimus is converted to a main metabolite hydroxy everolimus  is converted to a main 
metabolite hydroxy everolimus by the cytochrome 3A4 enzyme. The 30-hour half-life 
maintains a relative steady state achievable with the daily dosage regimen of 10mg/day. 
(Amato, 2011) 
In RECORD-1, a double-blind placebo-controlled phase III trial, 410 patients with advanced 
clear-cell RCC which had progressed after sunitinib, sorafenib or both, were randomized in 
a 2:1 ratio to everolimus 10 mg once daily or placebo plus best supportive care. Regardless 
of age, gender, prognostic group, previous treatment with sorafenib, sunitinib or both, 
prolongation of PFS (4.9 vs. 1.9 months; p< 0.0001) was found with everolimus over placebo. 
(Motzer et al, 2008) However there was lack of difference for median OS (14.8 months vs. 
14.4 months) as majority (80%) of patients in the placebo plus best supportive arm were 
allowed to cross over after the unbinding at the second interim analysis. This important 
landmark phase III trials proved the efficacy of mTOR inhibitors following VEGF therapy 
and as such received FDA registration for patients who have progressed following therapy 
with sunitinib and sorafenib. (Motzer et al, 2008) 
5. New agents in clinical development 
A number of second generation small molecule multi-targeted agents have been 
investigated in Phase II and III studies treating patients with metastatic RCC. (Fisher et al, 
2011) These include axitinib and tivozanib which are in advanced clinical development, as 
well as dovitinib and others. (Fisher et al, 2011)  
5.1 Axitinib 
Axitinib is a potent oral agent that inhibits VEGFR-1, -2 and -3. It is rapidly absorbed with 
peak plasma concentration occurring 1 - 2 hours after administration on an empty stomach, 
terminal half-life of 3 – 5 hours, and bioavailability of 58%. (Pithavala et al, 2010) Dose-
limiting toxicities seen in phase I studies were hypertension and mucositis, and in a phase II 
study, common adverse events also included diarrhoea and fatigue. ((Rixe et al, 2007b) 
Axitinib has been investigated in a number of different cancers including cytokine-
refractory metastatic RCC. A second line study in 52 patients using starting doses of axitinib 
5 mg twice daily, resulted in two complete and 21 partial responses (ORR of 44.2%). The 
median response duration was 23 months and median overall survival was 29.9 months. 
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(Rixe et al, 2007b) Updated 5 year OS data from this study were presented in abstract form in 
2011. (Motzer et al, 2011a) The 5 year survival rate was 20.6%. The ten patients surviving for 
more than five years had ORR 100% compared with 30% in <5 year survivors, took axitinib 
for longer (median 5.8 years vs. 0.67 years) and were fitter, with baseline ECOG PS of 0 in 
80% of the longer term survivors compared with 53% in <5 year survivors. However they 
were all similar age, gender and risk factors. No unexpected new toxicities were seen with 
prolonged use of axitinib.  
In a phase III second line study (AXIS), patients received axitinib at doses titrated up to 
10mg BD or sorafenib 400mg BD. (Rini et al, 2011b) The 723 patients had progressive disease 
after one prior first line treatment (sunitinib, bevacizumab, temsirolimus or cytokines). The 
ORR was 19.4% for axitinib vs. 9.4% for sorafenib (p=0.0001) and significantly longer PFS 
(12.1 versus 6.5 months, p<0.0001) was seen in patients on the axitinib arm. Patients who 
had previously received cytokines were found to have significantly (p<0.0001) better PFS 
with axitinib (12.1 months) than sorafenib (6.5 months). This also occurred in those having 
prior sunitinib (4.8 vs. 3.4 months, p=0.0107). As part of the same trial, patient-reported 
kidney specific symptom and function assessments were secondary endpoints. (Cella et al, 
2011) Outcomes according to validated tools were similar for both drugs during treatment, 
however as patients had a PFS with axitinib, this delayed worsening of the composite 
endpoint of cancer symptoms, progression or death compared with sorafenib. 
5.2 Tivozanib 
Tivozanib is an oral quinoline urea derivative small molecule TKI. It is a potent and 
selective inhibitor of VEGFR-1, -2 and -3 as well as inhibiting c-kit and PDGFR at higher 
concentrations. In 272 patients with advanced or metastatic RCC who had not received prior 
VEGF targeted therapy, tivozanib has shown promising efficacy and acceptable safety and 
tolerability in a phase II study reported in abstract form in 2011. (Nosov et al, 2011) All 
patients initially took tivozanib 1.5 mg daily for 16 weeks, and were then stratified 
according to response into stopping or continuing tivozanib, or if disease had stabilized, 
being randomised between tivozanib and placebo. Patients receiving placebo that 
developed progressive disease, or completed the double blind phase were allowed to restart 
tivozanib. Overall, 84% of patients demonstrated PR or SD by Week 16, ORR was 30%, 
disease control rate (DCR) was 85% and median PFS 11.7 months. Highest efficacy for 
tivozanib was in patients with clear-cell histology who had undergone a nephrectomy, who 
achieved an ORR of 36%, DCR of 88% and median PFS of 14.8 months. Commonest adverse 
effects included hypertension (45%) which was grade 3/4 in 12%, and dysphonia (22%). A 
low incidence of drug-related diarrhoea (12%), asthenia (10%), fatigue (8%), dyspnoea (6%), 
cough (5%), anorexia (5%), stomatitis (4%), hand-foot syndrome (4%) and proteinuria (3%) 
was reported. Overall median PFS, DCR and ORR were 11.7 months, 85% and 30%, 
respectively. Patients with clear-cell RCC who had undergone nephrectomy had PFS of 14.8 
months and ORR of 36% with tivozanib. Phase III evaluation of tivozanib in nephrectomised 
patients with advanced clear cell RCC is on-going. 
A phase Ib open-label study found tivozanib could be combined with temsirolimus at full 
dose/schedule in patients with advanced RCC (with clear cell component) who had failed 
up to one prior VEGF-targeted therapy. (Kabbinavar et al, 2011) Tivozanib was given orally 
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daily for 3 weeks on, 1 week off (1 cycle) and IV temsirolimus was given once weekly. A 
standard 3+3 dose escalation design was used at four levels from 0.5 mg to 1.5 mg per day 
and 15 to 25 mg per week of tivozanib and temsirolimus, respectively. There were 28 
patients (26 male) of median age 62 years and Karnofsky Performance Status from 100 to 80. 
Median duration of treatment was 21.1 weeks. Treatment-related adverse events seen in 
≥10% of patients were: fatigue (20 all grades/4 grade  3), decreased appetite (14/0), 
stomatitis (13/2), thrombocytopenia (10/4), diarrhoea (16/2), nausea (13/1), constipation 
(10/1), and dypsnoea (10/1). There were no grade 4 events, and no dose limiting toxicities. 
The MTD for the combination of tivozanib and temsirolimus was 1.5 mg/day and 25 
mg/week, respectively. PR was seen in 28%, SD in 64% and DCR (PR and SD>24weeks) of 
48%. The combination of tivozanib with temsirolimus was well tolerated and showed 
encouraging clinical activity in patients with advanced RCC. 
5.3 Dovitinib 
Dovitinib is a potent oral inhibitor of angiogenic factors, including the fibroblast growth 
factor (FGFR) and VEGF receptors. The maximum tolerated dose of dovitinib is 500 mg 
daily on a 5 day on/ 2 day off dosing schedule in 28 day cycles. A phase II study of 
dovitinib in clear-cell metastatic RCC patients previously treated with a VEGFR inhibitor 
and/or mTOR inhibitor was reported in 2011. (Angevin et al, 2011) (NCT1217931, 2011) In 51 
patients best overall responses were PR in 8%, and SD ≥ 4 months in 37%. Median PFS and 
OS were 6.1 and 16 months respectively. Fifty nine patients median age 60 years and ECOG 
PS 0 or 1 were evaluable for safety. The most common adverse events were nausea (73%; 
grade 3 : 9%), diarrhoea (64%; grade 3: 9%), vomiting (56%; grade 3: 5%), decreased appetite 
(48%; grade 3: 7%), asthenia (36%; grade 3: 12%), and fatigue (36%; grade 3: 10%). An on-
going phase 3 trial is comparing dovitinib with sorafenib in patients who have had one 
previous VEFR- and mTOR-targeted therapy.  
6. Combination therapy in metastatic RCC 
Despite being in the era where increasing numbers of VEGF and mTOR inhibitors are at the 
clinician’s disposal, their optimal use in patients with metastatic RCC has not been fully 
ascertained. Undeniably these agents have conferred significant survival benefits compared 
to historical series, however most patients eventually develop resistance and relapse after 6 
months to 3 years of therapy. (Jonasch et al, 2011) This underscores the strong need to 
develop novel treatment strategies to achieve better clinical outcomes. This could be 
achieved by the use of combinations of anti-angiogenic agents or with mTOR inhibitors, 
chemotherapy or immunotherapy. Sequencing treatment with different anti-VEGF agents as 
well as with mTOR inhibitors and immunotherapeutic agents could be another solution 
which will be discussed subsequently. (Jonasch et al, 2011) 
The concept of combining two (or more) targeted agents is biologically plausible as each agent 
may affect different targets simultaneously potentially resulting in additive or synergistic 
effects and achieving better clinical outcomes. (Hutson, 2011) Using a combination of drugs 
which target the same pathway (e.g. VEGF) at two or more different levels, has been termed 
”vertical blockade”. In contrast, “horizontal blockade” occurs when the different pathways are 
blocked simultaneously by one or multiple agents in combination. (Hutson, 2011) It should be 
www.intechopen.com
 
Emerging Research and Treatments in Renal Cell Carcinoma 
 
384 
noted that combination therapy is often undertaken at the cost of increased toxicities as 
evidenced by some of the phase I trials where sunitinib was combined with temsirolimus, 
bevacizumab or everolimus. (Feldman et al, 2009; Rini et al, 2009) 
6.1 VEGF-ligands or receptor inhibitors / mTOR plus immunotherapy combination 
This is best illustrated by the two single arm phase II studies combining sorafenib with 
standard dose of IFN-ǂ which conferred higher ORR (approximately 30%) and longer PFS (7 
– 12 months) when compared with phase III data of sorafenib monotherapy. (Gollob et al, 
2007; Ryan et al, 2007) However, in a randomised phase II study comparing sorafenib 
monotherapy with sorafenib /low-dose IFN-ǂ combination, a very similar response rates 
and longer PFS were demonstrated equally in both arms. Interpretation of these phase II 
data required caution given the small number of patients recruited in comparison with the 
more robust phase III sorafenib vs. placebo trial. (Jonasch et al, 2010) 
The AVOREN and CALBG 90206 trial demonstrated that the bevacizumab / IFN-ǂ 
combination had achieved better clinical outcome when compared with IFN-ǂ alone. 
(Escudier et al, 2007c; Rini et al, 2008) Unfortunately, the lack of bevacizumab as a control 
arm did not help address the question as to whether the addition of IFN-ǂ to bevacizumab 
was able to achieve a more superior outcome compared to bevacizumab alone. A small 
randomised phase II study comparing erlotinib and bevacizumab with bevacizumab alone 
reported a non-statistical small PFS difference of 0.5 months (9.0 months vs. 8.5 months; 
p=0.58). Although this is small benefit may be clinically irrelevant, this trial provided insight 
into the clinical efficacy of bevacizumab as monotherapy. (Bukowski et al, 2007b) 
A randomised three-arm trial was undertaken comparing temsirolimus (25mg) / bevacizumab 
(10mg/kg) combination with sunitinib alone and with IFN-ǂ (9X 106 IU thrice weekly) / 
bevacizumab (10mg/kg) combination in patients with advanced RCC (TORAVA). A total of 
171 treatment naϊve patients were recruited in a 2:1:1 ratio and was equally distributed into the 
three arms. The reported median FPS was similar (8.2 months) for both temsirolimus (25mg) / 
bevacizumab (10mg/kg) (experimental) arm and sunitinib (comparator) arm. The duration for 
bevacizumab / IFN-ǂ was however up to 16.8 months. The patients in the experimental arm 
experienced a high number of discontinuation from treatment for reasons other than 
progression (51%) when compared to the sunitinib arm (12%) and bevacizumab / IFN-ǂ arm 
(38%). (Negrier et al, 2011) Furthermore up to 77% in the experimental arm experienced a 
grade 3 or higher toxicity. The trial again highlighted the lack of survival benefit due to a toxic 
combination that is poorly tolerated and the investigators appropriately commented that this 
combination would not be recommended for first-line treatment in patients with metastatic 
RCC. (Negrier et al, 2011) Similarly, when temsirolimus was prescribed in conjunction with 
IFN-ǂ in a phase III trial for patients with poor prognostic advanced RCC, the overall survival 
benefit was worst in the tmesirolimus / IFN-ǂ arm compared to temsirolimus monotherapy 
arm. Once again, toxicity prevailed in the combination arm and therefore the temsirolimus / 
IFN-ǂ combination is not recommended as standard practice yet outside a clinical trial for 
treatment of advanced RCC. (Hudes et al, 2007) 
6.2 VEGF-ligands or receptor inhibitors / mTOR combination 
Sorafenib like sunitinib was also investigated in combination with bevacizumab in two 
phase I studies. In one the study of patients with metastatic RCC, the median time to 
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progression was 11.2 months and the partial response rate was 46%. (Sosman et al, 2008) 
In the second trial which included 39 patients with solid tumours (with 3 patients with 
RCC), PR or disease stabilisation of ≥4 months was observed in 59% of the assessable 
patients, and a PR was achieved in one of the 3 patients with RCC. (Azad et al, 2008) The 
combination arm required dose reduction of both agents and resulted in a considerably 
lower maximum tolerated dose compared to maximal tolerated dose of the single agent. It 
is postulated that bevacizumab most likely enhanced the side-effects of sorafenib such as 
hypertension and hand-foot syndrome. (Azad et al, 2008; Sosman et al, 2008) When 
sunitinib was combined with bevacizumab, a high incidence of haematological and 
vascular toxicities (including microangiopathic haemolytic anaemia) and hypertension 
were observed. (Feldman et al, 2009) Again bevacizumab was likely responsible for the 
exaggeration of the side-effects of sunitinib which would have been otherwise 
manageable.  
Finally, a phase II trial examining the feasibility, tolerability, and efficacy of multiple 
combinations of currently available therapies are being tested in the Eastern Cooperative 
Oncology BeST trial. The four arms are bevacizumab (10mg/kg), bevacizumab (5mg/kg) 
/temsirolimus (25 mg), bevacizumab (5mg/kg) and sorafenib (200mg twice daily)/ 
temsirolimus (25mg). (NCT00378703, 2006) This trial will provide insight into the efficacy of 
bevacizumab monotherapy and the clinical tolerability and efficacy of lowered dose of 
bevacizumab and sorafenib dose in conjunction with temsirolimus where previously 
significant toxicities was noted on the earlier phase II studies.  
7. Sequencing therapy in metastatic RCC  
Sequencing the systemic treatment of metastatic RCC has several potential benefits. 
Sequential treatment is less toxic than combination therapy and thus allowing patients to be 
exposed to a more optimal dose (and subsequent higher total accumulative dose) resulting 
in improved clinical efficacy. It also creates a treatment continuum with the goal of maintain 
responding patients on treatment for as long as clinically feasible. Lastly, targeting the 
different pathway at different point in time theoretically offers the benefit of overcoming the 
resistance to the individual agents. (Bellmunt, 2009) 
7.1 Antiangiogenic therapy after immunotherapy 
A phase II study published in 2003 examined the role of bevacizumab (10mg/kg) post 
progression on immunotherapy demonstrated a time-to-progression (TTP) of 4.8 months. 
(Yang et al, 2003) Two phase II trials mentioned earlier on similarly examined the efficacy of 
sunitinib post immunotherapy revealed promising survival benefits which subsequent led 
to the landmark phase III trial comparing sunitinib with IFN-ǂ. (Motzer et al, 2006; Motzer et 
al, 2007b) The phase III sorafenib trial vs. placebo (TARGET) also recruited patient who had 
cytokine therapy and observed a doubling of PFS benefit of 2.8 to 5.6 months. (Escudier et al, 
2007b) More recently, in a phase II trial examined the use of axitinib post cytokine therapy 
demonstrated a TTP of 15.7 months. (Rixe et al, 2007b) Whilst it is possible to compare the 
results of each individual phase II trials and rank them to their clinical benefit, a proper 
conducted phase III is essential to determine the best anti-angiogenic agent to use post-
cytokine therapy.  
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7.2 mTOR blockade after anti-angiogenic therapy 
The best illustrating example is the RECORD-1 trial which investigated the benefits of 
everolimus vs. placebo with best supportive care post progression on sunitinib, sorafenib or 
both. Of note 71% of patients had received prior sunitinib whilst 55% sorafenib. Patient that 
received everolimus achieved an additional of 3-month of PFS benefit regardless whether they 
received sunitinib  or sorafenib. No overall survival benefits were noted due to large numbers 
of patients from placebo crossing over to everolimus arm (80%). (Motzer et al, 2008) 
An on-going trial (RECORD-3) will randomly assign patients between either everolimus or 
sunitinib where at first sign of progression, patients would cross over to sunitinib if they 
were on everolimus and vice versa. The primary end point of this trial is to assess whether 
PFS after first-line treatment for patients who received everolimus will be non-inferior to 
patients who receive sunitinib after first-line therapy. (NCT00720941, 2011) 
7.3 Serial anti-angiogenic agents 
Axitinib has been investigated in both phase II and III second-line trials in advanced RCC. 
The results of the survival benefits have so far been encouraging especially in the phase III 
trial comparing with sorafenib. (Dutcher et al, 2008) Further trials will be undertaken clarify 
the outcomes. Specifically, in the Sequential Two-agent Assessment in Renal Cell Carcinoma 
Therapy (START)  two hundred and forty treatment-naïve patients with clear-cell 
component mRCC will be randomly assigned to receive bevacizumab, pazopanib, or 
everolimus. On first progression or intolerance to therapy, patients will be randomly 
assigned to one of two of the remaining agents. The primary end point is the detection of the 
longest combination of the TTP. (NCT1217931, 2011)   
A retrospective study described the efficacy of sorafenib or sunitinib in the first-line setting 
in 49 patients with metastatic RCC as well as the subsequent derived benefit after switching 
to the alternative agent on progression. (Dudek et al, 2009) The TTP for patients treated with 
sunitinib or sorafenib (after initial treatment) was 5.8 and 5.1 months respectively (p=0.299). 
However, sequential treatment with sorafenib followed by suntinib resulted in a trend 
toward improved TTP (p = 0.115). Similarly, the median OS was better for patients who 
received sorafenib followed by sunitinib (23.5 months) than if they received sunitinib after 
sorafenib (10.4 months; p=0.061). This analysis of median survival did not include patients 
who did not need to cross over. This retrospective study suggested the benefit of utilizing 
sorafenib as first line may improve duration of disease control if a subsequent agent is used 
and certainly warrants further investigation. (Dudek et al, 2009) The SWITCH trial is a 
prospective phase III trial which will randomize patients to upfront sunitinib and switching 
to sorafenib on progression versus switching from sorafenib to sunitinib on progression. The 
primary end point is the PFS and hopefully this trial will show further insight into which 
anti-VEGF treatment sequence will confer better clinical outcome in patients with metastatic 
RCC. (NCT00732914, 2010) 
8. Systemic treatment for non-clear-cell RCC 
The treatment for advanced non-clear-cell RCC is less well established than the clear-cell 
variants and the evidence to guide treatment is limited. Majority of the data is derived from 
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expanded access trials, retrospective series, and subset analyses of major trials. (Tazi el et al, 
2011) The phase III sunitinib trial virtually excluded all patients with non-clear-cell RCC. In 
spite of this, sunitinib was made available to all patients with clear-cell and non-clear-cell 
histology in a subsequent multi-centre, international, non-randomized expanded access 
compassionate trial. (Motzer et al, 2007a) A total of 588 patients with non-clear cell histology 
(not characterized further) received sunitinib and of that, 437 evaluable patients 
demonstrated an ORR of 11% (n=48) with 46 partial responders and 2 complete responders) 
and 57% had stable disease (n=250) for at least 3 months. (Gore et al, 2009) The median OS 
was 13.4 months. The ORR of 11% was lower than the original phase III study and was 
thought to due to the non-mandatory reporting of the disease response and the reliance of 
local practice to detect any change in the disease burden. The authors of the study therefore 
concluded that sunitinib is active in subjects with non-clear- cell histology amongst other 
subsets of patients (poor performance status, brain metastasis and patients of ≥ 65 years old) 
which were not enrolled in the original trial. (Motzer et al, 2002) 
One of the largest retrospective series for papillary RCC was a multi-centre review 
consisting of 41 patients treated with either sunitinib or sorafenib. The response rate was 
disappointing with an ORR of 5% for all comers but was higher at 17% for sunitinib. The 
PFS was statistically longer for patients treated with sunitinib (11.9 months) when compared 
with sorafenib (5.1 months; p <0.001). The PFS for sunitinib was comparable to the phase III 
clear-cell trial suggesting clinical efficacy in sunitinib for papillary carcinoma. (Choueiri et al, 
2008) In contrast, two small phase II studies showed little-to-no clinical response and disease 
stability being the best clinical response for only a short duration of 1.4 to 3 months. 
(Plimack et al, 2010; Ravaud et al, 2009) 
The efficacy of sorafenib in the treatment of advanced papillary variant is best demonstrated 
in the Advance Renal cell Carcinoma Sorafenib Expanded Access Program in North 
America. One hundred and fifty eight patients with papillary RCC were enrolled. Of the 107 
patients with papillary RCC that could be evaluated, 84% (n=90) demonstrated 3 PR and 87 
SD for a duration of 8 weeks or more. Sixteen percent (n=17) of patients showed early 
progression of disease. (Beck et al, 2008) 
The phase III international, multicentre trial, comparing temsirolimus, IFN-ǂ, or 
combination of both, is the first trial that prospectively recruited all histological subtypes of 
RCC. Twenty percent (n=120) were classified as non-clear cell RCC without further 
subclassification at the outset due to the absence central pathology review. (Hudes et al, 
2007) An improvement in the median OS and median PFS were seen in the temsirolmus 
monotherapy arm compared to the combination temsirolimus/IFN-ǂ or IFN-ǂ 
monotherapy arm. Subsequent exploratory subset analyses based on tumour histology 
determined that 55 patients that had papillary RCC also demonstrated an OS and PFS 
benefit when treated with temsirolimus. (Schmidt et al, 2001) The OS and PFS for 
temsirolimus vs. IFN-ǂ were 11.6 months vs. 4.3 months and 7.0 months vs. 1.8 months 
respectively. These results led to the subsequent FDA approval of temsirollimus as 
treatment for non-clear-cell histology in advanced RCC. Everolimus has demonstrated 
efficacy in the pivotal trial for patients with clear-cell RCC, post progression on sunitinib, 
sorafenib or both in the RECORD-1 trial. (Motzer et al, 2008) This has prompted the 
development of an open-label, single arm, multi-centre phase II examining the efficacy of 
everolimus as first-line systemic therapy for patients with advanced papillary RCC. (Amato, 
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2011) Central confirmation of histology and subclassification into type I and II will be 
undertaken. This trial which is still recruiting will hopefully show further insight into the 
treatment of papillary RCC which thus far has been disappointing.  
Erlotinib was examined in a phase II study in treatment naïve patients with locally 
advanced or metastatic papillary RCC. (Gordon et al, 2009) Of the 52 registered patients, 45 
were evaluable. The ORR was 11% (n=5) and the DCR was 64% with five partial responders 
and 24 patients with stable disease. The median OS time was 27 months with a 29% 
probability of freedom from treatment failure at 6 months. The presence of EGFR receptors 
scores and staining intensity determined by immunohistochemistry showed no correlation 
with TTP or OS. The estimated median survival was estimated to be 27 months. (Gordon et 
al, 2009) Combination of erlotinib with bevacizumab is currently underway designed to 
further evaluate the efficacy of erlotinib. (2010) 
As with papillary variant of RCC, the chromophobe variant has also been excluded from 
many of the initial targeted therapy trials. Not surprisingly the data is even more limited. 
Furthermore, with the low incidence of 4% and the low likelihood of chromophobe to 
metastasize, any attempts to recruit patients of this type into a clinical trial is a difficult 
process. In the sorafenib access program described earlier, an overall DCR of 90% was noted 
with 5% (n=1) demonstrating partial response and 85% (n=17) of the patients experiencing 
disease stability for at least 2 months. (Stadler et al, 2010) The chromophobe variant were 
also included in the phase III temsirolimus versus IFN-ǂ trial but the subgroup analysis only 
focused on papillary variant and the data for chromophobe was therefore not published. 
Nevertheless the PFS and OS were prolonged in the non-clear cell subgroup, therefore 
hinting some weak evidence of efficacy in this group of tumour. (Tazi el et al) 
The strongest treatment evidence for treatment of the rare collecting duct renal cell 
carcinoma stemmed from a phase II multi-centre trial of 23 treatment-naïve patients who 
received cisplatin or carboplatin if inadequate renal function with gemcitabine. This variant 
is very aggressive and patient often presents with more advanced stage and succumbed 
earlier. This combination was selected based on some similarities in the histological features 
comparing with transitional cell carcinoma of the urinary bladder. In the trial, there was an 
observed ORR of 26%. The median PFS and OS were 7.1 months and 10.5 months. (Oudard 
et al, 2007a) To date, there is very little data to support the use of anti-VEGF therapies in this 
very bad prognostic cancer.  
9. Side effects of targeted therapies used in renal cell carcinoma 
The clinical benefit of newer targeted agents in metastatic RCC over previous conventional 
treatment has been shown in Sections 1 to 5 in this chapter. However as with any new 
treatment, sideeffects must be carefully measured and evaluated against older treatments 
and supportive or pharmacologic interventions developed for their prevention or control. 
(di Lorenzo et al, 2011) This is essential when considering patients’ quality of life (see Section 
11) and should allow patients to stay on beneficial treatment for as long as possible. 
(Bellmunt, 2007) Safety data from clinical trials and post-marketing surveillance have 
identified that many of the targeted therapies have toxicities that are different from those 
usually seen with conventional anticancer drugs. (di Lorenzo et al, 2011; Ravaud, 2011) 
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These angiogenesis inhibitors directly or indirectly target the VEGF pathway, and their 
individual mechanisms are pointers to their toxicities. (Schmidinger & Bellmunt, 2011) They 
share several adverse effects in common, including hypertension, fatigue, gastrointestinal, 
skin, and bone marrow effects. The mTOR inhibitors can cause metabolic alterations, 
immunosuppression and interstitial pneumonitis, whereas hypothyroidism is seen in 
patients taking sunitinib, potentially sorafenib and pazopanib. (di Lorenzo et al, 2011) 
Suggestions for management are shown below. The importance of patient education with 
respect to self-management strategies has been emphasized. (Ravaud, 2011) 
9.1 Hypertension  
Hypertension is a well recognised class side effect commonly observed in cancer patients 
treated with angiogenesis inhibitors that target the VEGF pathway, but not with mTOR 
inhibitors. (Izzedine et al 2009, diLorenzo 2011) Hypertension is reported with axitinib, 
bevacizumab, sorafenib, sunitinib and pazopanib. (Escudier et al, 2007b; Motzer et al, 2007a; 
Rini et al, 2011a; Rixe et al, 2007a; Sternberg et al, 2010) Hypertension has occurred whether 
or not the patient has a history of high blood pressure, however incidence may be higher in 
patients with pre-existing cardiovascular disease. Reversible posterior leukoencephalopathy 
syndrome is a rare association with hypertension seen with sunitinib and sorafenib where 
patients in addition experienced seizures and impaired vision thought to be attributed to 
capillary leakage and vasogenic oedema of the brain. This is reversible with cessation of the 
implicated agent. (Kapiteijn et al, 2007) Hypertension is an independent risk factor for the 
onset of cardio- and renovascular disease. In patients with metastatic disease, the goal of 
optimizing blood pressure is to allow continuous and safe administration of the anti-VEGF 
agents. (Izzedine et al, 2009; Keefe et al, 2011) Blood pressure monitoring (either daily or 
multiple times per week) is recommended and the use of antihypertensive medication may 
be required to avoid potential cardiovascular complications. Algorithms for hypertension 
management have been developed, (di Lorenzo et al, 2011) and treatment should be 
individualised to the patient. (Izzedine et al, 2009) The best anti-hypertensive agents is yet to 
be determined, however an angiotensin-converting enzyme (ACE) inhibitors is a logical 
choice if bevacizumab is the underlying cause as they may improve the associated 
proteinuria. (Keefe et al, 2011) Angiotensin II inhibitors, diuretics, hydropyridine calcium 
channel blockers (CCBs), and ǃ-blockers are also possible anti-hypertensive agents. In 
patients on anti-hypertensive medications at baseline, an increase in the dose of pre-existing 
antihypertensive medications may be required. Temporary suspension of therapy may be 
required to allow for better control of the hypertension. In some cases, severe hypertension 
with life-threatening consequences (e.g. malignant hypertension, transient or permanent 
neurologic deficit, hypertensive crisis) has led to permanent discontinuation. (Keefe et al, 
2011) The relationship between hypertension and anti-tumour effect is postulated with 
several of the drugs used for renal cell cancer and this will be addressed in Section 10. 
9.2 Fatigue  
Fatigue is the commonest of the constitutional side effects seen with the targeted agents 
used in metastatic RCC, but is less common than with cytokine treatment. (Adams & 
Leggas, 2007; di Lorenzo et al, 2011; Hutson, 2011; Motzer et al, 2007a) The  incidence of 
fatigue in Phase III studies ranged from 14% to 51% for all grades, up to 11% for grade 3–4. 
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(di Lorenzo et al, 2011) Patients with cancer-related fatigue experience a chronic feeling of 
tiredness or lack of energy that is not relieved by rest. Fatigue can be caused by the targeted 
therapy and/or aggravated by other factors, such as anaemia, anxiety, hypothyrodism or 
depression, nutritional status, side effects of other medications or even organ dysfunction. 
(di Lorenzo et al, 2011; Ravaud, 2009) Patients may find it useful to record a daily fatigue 
diary to see when their energy levels are highest during the day in order to allow 
themselves time and energy for activities they enjoy. Evidence-based pharmacological 
interventions remain scarce, but monitoring and treating patients for any aggravating 
factors may help. If grade 3–4 fatigue persist, it may be necessary to dose reduce or stop 
treatment. (di Lorenzo et al, 2011; Ravaud, 2009) 
9.3 Gastrointestinal side effects  
Gastrointestinal toxicities are common to most of the targeted therapies for RCC but rarely 
lead to dose interruptions. (di Lorenzo et al, 2011) These include diarrhoea, nausea and to a 
lesser degree vomiting. Standard protocols used in prevention and treatment of these 
toxicities in patients having cytotoxic chemotherapy are suitable for use in this setting. 
Supportive medications will include loperamide (up to 16mg per day) for diarrhoea; 
dopamine antagonists such as metoclopramide or where necessary 5HT3 receptor 
antagonists for nausea and vomiting. (di Lorenzo et al, 2011)(di Lorenzo 2011)  Oral 
mucositis is also reported with the mTOR inhibitors everolimus and temsirolimus, and the 
tyrosine kinase receptor inhibitors. Evidence-based guidelines advise good oral hygiene, 
local anaesthetic mouthwashes or systemic analgesics if required for mouth pain, and 
avoidance of alcohol based mouthwashes. (see www.mascc.org)  
9.4 Dermatological side effects 
Various dermatological side effects can be seen with all of the agents used in metastatic 
RCC. Prevention and management is important to maintain patients’ health-related quality 
of life as well as treatment dose intensity. (Lacouture et al, 2011) Toxicities seen  include 
papulopustular (acneiform) rash, hair changes (including alopecia, colour changes), 
dermatitis enhancement, pruritus, xerosis, skin fissures, paronychia and hand-foot skin 
reactions (HFSR). (di Lorenzo et al, 2011; Lacouture et al, 2011)  HFSR appears as plaques or 
blisters with painful tingling or burning sensations in the soles of the feet or palms of the 
hands, and these effects are particularly common with sorafenib and sunitinib. (di Lorenzo) 
Avoiding tight shoes, and using moisturiser, emollient creams and topical treatment 
containing urea or salicyclic acid is suggested. (di Lorenzo et al, 2011; Ravaud, 2009) 
Evidence-based treatment guidelines for managing skin toxicities have recently been 
published by the MASCC Skin Toxicity Study Group (Lacouture et al, 2011) Topical 
hydrocortisone cream (1 %) and oral antibiotics (doxycycline or minocycline) are the 
mainstay of prevention of papulopustolar rash or if they are painful. (Lacouture et al; 
Ravaud, 2009) 
9.5 Other reported adverse effects 
Clinical hypothyroidism defined as a decrease in free thyroxine index with elevated thyroid 
stimulating hormone levels has been reported in patients taking sunitinib, pazopanib and 
sorafenib (the latter specifically in Japanese subjects). (di Lorenzo et al, 2011) Screening pre-
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treatment and on days 1 and 28 each cycle, and use of thyroxine is advised. (di Lorenzo et al, 
2011) 
Heart failure is seen with a number of targeted agents including sunitinib, bevacizumab and 
sorafenib. (Jarkowski et al, 2011) Patients, especially those with pre-existing cardiovascular 
disease, should be closely monitored especially if they have cardiac risk factors. (Ravaud, 
2011) If heart failure occurs it should be managed according to standard protocols, and the 
offending agent ceased. (Jarkowski et al, 2011) Myocardial ischaemia or infarction was 
significantly more frequent in patients taking sorafenib group (3%) than placebo. 
Severe and fatal hepatotoxicity (boxed warning) and grade 3 or 4 proteinuria have occurred 
with pazopanib treatment which necessitates routine monitoring of liver function tests, and 
urinalyses. (Ravaud, 2011)  
Venous and arterial thromboses have been reported in patients on bevacizumab. (Escudier 
et al, 2007c; Rini et al, 2008) Both sunitinib and sorafenib are also associated with 
thromboembolic events although the rates are lower to bevacizumab. (Keefe et al, 2011) The 
role of therapeutic anticoagulation for venous thrombosis and aspirin for arterial thrombosis 
are currently being undertaken given the increased use of the anti-VEGF agents not only in 
metastatic RCC but in other advance cancers such as non-small cell lung cancer and 
colorectal carcinoma. (Keefe et al, 2011) Pazopanib has also been associated with arterial 
thrombotic events including myocardial infarction or ischaemia, cerebrovascular accidents 
and transient ischaemic attacks. Incidence was 3% of patients on pazopanib compared with 
none in patients taking placebo. (Sternberg et al, 2010) The incidence of haemorrhagic events 
(all grades) in the pazopanib arm was 13% compared with 5% with placebo. (Sternberg et al, 
2010) 
Other agent-specific side effects include adrenal insufficiency, especially in the setting of 
increased physical stressors with sunitinib; (Desai et al, 2007) hyperglycaemia, 
hyperlipidaemia and acute infusion reactions with temsirolimus (Hudes et al, 2007); and 
non-infectious pneumonitis in patients receiving everolimus, or temsirolimus. (Ravaud, 
2011) Patients with pneumonitis may exhibit few if any symptoms and the diagnosis is 
radiological. Monitoring is advisable although pneumonitis resolves spontaneously when 
the mTOR inhibitor is ceased and rarely requires use of corticosteroids. (Hudes et al, 2007) 
Lastly, thrombotic microangiopathy has been reported in association with suntinib, 
sorafenib, and bevacizumab, either as combined or as single agents. The manifestations 
included thrombocytopenia, haemolytic anaemia with schistocytosis, and renal dysfunction. 
(Kapiteijn et al, 2007; Patel et al, 2008) The treatment of this condition would involve the 
cessation of the implicated agent and plasma exchange. (Frangie et al, 2007) 
10. Hypertension as biomarker of efficacy of sunitinib 
Data from the two second-line phase II trials, one first-line phase III trial, and an 
expanded access study of sunitinib were retrospectively analysed to determine whether 
there was a relationship between hypertension and anti-tumour effect. (Rini et al, 2011a) 
Hypertension in this context was defined by either maximum or mean systolic blood 
pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90 mmHg, measured 
on days 1 and 28 of each 6-week treatment cycle at any time during the study after the 
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first dose of sunitinib. (Rini et al, 2011a) The ORR was 54.8% in hypertensive patients vs. 
8.7% in patients without a maximum SBP of at least 140 mmHg. Median PFS was 12.5 
months vs. 2.5 months, and median OS was 30.9 months vs. 7.2 months in the same two 
cohorts respectively. (Rini et al, 2011a) Overall, a better clinical outcome was 
demonstrated in patients who experienced hypertension and indeed a direct correlation 
between SBP and DBP and clinical outcome was observed. To determine whether or not 
antihypertensive medications reduced the anti-tumour efficacy of sunitinib, clinical 
outcomes were compared in patients using medications with those that were not at 
baseline, after cycle 1 and cycle 2. No statistical differences were noted in the ORR or the 
PFS between the two cohorts regardless of the presence of anti-hypertensive treatments at 
baseline. The median PFS in the treated and not on antihypertensive were 11.3 months 
and 10.6 months respectively (p=0.20). There was however a significant difference in 
median OS of more than 10 months with patients on anti-hypertensive medications 
demonstrating a 31.8 month survival vs. 21.4 months for patients not taking anti-
hypertensive agents (p <0.001). The results of median PFS and median OS measured in 
patients with or without hypertension at the end of cycle 1 and 2 mirrored those obtained 
at baseline. (Rini et al, 2011a) To illustrate, median PFS measured at the end of cycle 1 for 
patients with and without anti-hypertensive agents were 13.4 months vs. 10.8 months  
respectively (p=0.31) and at the end of cycle 2, the median PFS were 13.6 months vs. 10.8 
months respectively (p=0.15). (Rini et al, 2011a)The overall survival benefit at the end of 
cycle 1 for patients on anti-hypertensive and not on anti-hypertensive were 30.1 months 
vs. 23.3 months (p=0.155) and for cycle 2 was 31.1 months vs. 23.0 months (p=0.013) 
respectively. When analysed according to the prognostic factors (ECOG performance 
status, time from diagnosis to treatment, LDH, platelet count, corrected calcium), 
treatment induced hypertension remained a statistically significant predictor of survival 
benefit (p<0.001). (Rini et al, 2011a) In spite of these results supporting the hypothesis that 
hypertension may be a viable biomarker of anti-tumour efficacy, the development of 
hypertension during sunitinib treatment was neither necessary nor sufficient for clinical 
benefit in all patients.(Rini et al, 2011a) 
11. Drug interactions 
The targeted agents are predominantly metabolized by the hepatic cytochrome P450 enzyme 
CYP3A4 which raises the possibility of drug- drug interactions with concomitant 
medications that are strong inducers or inhibitors of CYP3A4 (Table 1). (Adams & Leggas, 
2007; di Lorenzo et al, 2011; Kollmannsberger et al, 2007b) For example, the CYP3A4 
inhibitors that would potentially increase toxicity of targeted agents include antiretroviral 
agents such as ritonavir, indinavir and nelfinavir, and antibiotics/antifungals such as 
clarithromycin, ketoconozole, fluconazole, itraconazole and voriconazole. Potent CYP3A4 
inducers that decrease therapeutic efficacy of the targeted agents would include 
antiepileptic medications such as phenytoin and carbamazepine; antibiotics such as 
rifampicin and rifabutin. (Kollmannsberger et al, 2007a) If the interacting concomittant agent 
cannot be stopped, doses of the targeted agents may need upward or downward adjustment. 
It is not only drug-to-drug interactions that are of concern, as many patients take 
supplements or complementary and alternative medicines (CAM) which they may not 
mention to their treating physicians. (Lees & Chan, 2011) Hypericum perforatum, commonly  
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Targeted agent Possible clinical effect Recommended 
management 
sunitinib    
carbamazepine 
phenytoin 
primidone 
 
Decreased blood levels of 
sunitinib, potential for 
reduced effect 
 
Avoid concurrent use, 
choose a non-interacting 
anti-epileptic agent or 
consider  increasing 
sunitinib dose; monitor 
closely for effect and 
tolerability 
St John’s Wort Decreased blood levels of 
sunitinib, potential for 
reduced effect 
Avoid concurrent use 
sorafenib   
carbamazepine 
phenytoin 
primidone 
Decreased blood levels of 
sunitinib, potential for 
reduced effect 
 
Avoid concurrent use, 
choose a non-interacting 
anti-epileptic agent or 
consider  increasing 
sorafenib dose; monitor 
closely for effect and 
tolerability 
warfarin Increased  INR, bleeding Monitor patient’s INR 
closely 
everolimus   
ketoconazole 
itraconazole 
fluconazole 
voriconazole 
Increased blood levels of 
everolimus; potential for 
toxicity  
Avoid concurrent use or 
consider  reducing 
everolimus dose; monitor 
closely for effect and 
tolerability 
phenytoin Decreased blood levels of 
everolimus, potential for 
reduced effect 
 
St John’s Wort Decreased blood levels of 
everolimus, potential for 
reduced effect 
Avoid concurrent use 
Table 1. Selected examples of drug interactions with some targeted agents 
known as St John’s Wort  is a herbal preparation cancer patients may well be taking for its 
supposed antidepressant benefits. As it is a CYP3A4 enzyme inducer if taken with sunitinib,  
sorafenib or everolimus, for example, their effects may be decreased. Grapefruit juice is 
known to be a CYP3A4 enzyme inhibitor and as such may lead to unexpected toxicity if 
taken with sunitinib. (Kollmannsberger et al, 2007a) A comprehensive full medication 
history incuding prescribed, self-prescribed over the counter and CAM should be taken 
when any patient is about to start treatment. (di Lorenzo et al, 2011; Lees & Chan, 2011) 
Drug interaction databases should be utilised, since more reports of interactions may appear 
as experience with these newer therapies increases. 
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12. Quality of life in patients with renal cell carcinoma receiving targeted 
therapies 
Health-related quality of life (QoL) has been assessed in a number of studies of patients 
taking newer targeted therapies for RCC (or kidney cancer). Questionnaires used have 
included the Functional Assessment of Cancer Therapy-General (FACT-G), the FACT-
Kidney Symptom Index-15 item (FKSI-15), the FACT-Kidney Symptom Index-Disease 
related Symptoms (FKSI-DRS), the European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30 and the Euro QOL 5D (Index and 
Visual Analogue Scale) utility score (EQ-5D) Index. 
Sunitinib has shown improvement over IFN-ǂ with clinically meaningful differences both in 
kidney cancer related symptoms and overall QoL. (Motzer et al, 2007a) Sorafenib when 
compared with placebo, showed no difference in QoL based on the FACT-G or FKSI-15 
mean scores in a sub-analysis of the TARGET trial. However certain symptoms such as 
fevers, ability to enjoy life, dyspnoea and cough as well as concerns for well being were 
reported less in the patients on sorafenib. (Bukowski et al, 2007a) Quality of life was assessed 
as a secondary end point in the pazopanib vs. placebo phase III trial (EORTC-QLQ-C30 
Version 3) and EQ-5D Index. Patients on pazopanib did not have a clinically different QoL 
compared with placebo, despite the toxicities that may be expected with pazopanib. 
(Sternberg et al, 2010) 
More recently, patient-reported kidney-specific symptom and function assessments as 
secondary endpoints of the AXIS trial (axitinib vs. sorafenib) were reported at ASCO 2011 
(Cella et al, 2011). Over 700 patients randomised to axitinib or sorafenib completed FKSI-15 
and its disease-related symptoms subscale FKSI-DRS with a completion rate of about 90%. 
(Cella et al, 2011) Overall estimated means in the FKSI-15 and FKSI-DRS mixed-effects 
models were similar between treatments. The composite time to deterioration (TTD) 
endpoint, using FKSI-15 or FKSI-DRS, showed a 25% risk reduction for axitinib vs. sorafenib 
(p=0.0001 for both comparisons). Axitinib treatment resulted in patient reported outcomes 
comparable to sorafenib in patients being treated for second-line metastatic RCC. The PFS 
benefit demonstrated by axitinib is accompanied by a delay in worsening of the composite 
endpoint of advanced RCC symptoms, progression, or death compared with sorafenib. 
These data reporting on improved or unchanged QoL during treatment with anti-VEGF 
tyrosine kinase inhibitors (TKIs) are reassuring and may well allay any fears that patient 
may have and in fact encourage them to proceed on with the treatment. Indeed, the 
improvement of QoL with some of the TKIs may be attributed to the resolution of their 
cancer-related-symptoms from the treatment.  
In a double-blind, placebo-controlled trial, everolimus 10 mg daily was evaluated using 
FKSI-DRS and EORTC QLQ-C30. (Beaumont et al, 2011) Longitudinal trends for FKSI-DRS 
scores did not differ between everolimus and placebo. For physical functioning and global 
QoL, a small but statistically significant decrease was seen with everolimus. All three 
measures were significantly related to PFS. The authors reported that even when 
progression of disease was delayed by the new treatment, it did not affect patients’ 
symptoms, functioning, or their QoL, which they proposed is something patients, their 
family and healthcare providers might expect. (Beaumont et al, 2011) Furthermore, 
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Beaumont and colleagues suggest that for patients receiving first line treatment with a 
targeted agent, the prospect for clinical benefit may outweigh concerns about health-related 
QoL. However, in contrast, when these agents are being used in the second- and third-line 
settings, health-related quality of life may be of more importance to all concerned groups. 
Continued research is needed into the positive and negative outcomes associated with new 
treatments for metastatic RCC. (Beaumont et al, 2011)  
13. Pharmacoeconomics 
It is important to determine the optimal setting and sequence of new targeted agents in 
metastatic RCC to improve patient survival outcomes whilst considering cost-effectiveness. 
Comparative cost-effectiveness in the first- and second-line setting should be assessed with 
respect to life years gained. (Molina & Motzer, 2011) For example, Benedict and colleagues 
utilized a Markov model simulating disease progression, adverse events and survival to 
assess economic value of first-line treatments in the US and Sweden. Their analyses 
suggested sunitinib is cost-effective compared with sorafenib, or bevacizumab plus IFN-ǂ 
for first line metastatic RCC treatment. (Benedict et al, 2011)  In 2011 NICE, the UK National 
Institute for Health and Clinical Effectiveness, was unable to approve everolimus for 
second-line  metastatic RCC as it was too expensive for the benefit provided. 
(http://guidance.nice.org.uk/TA219/Guidance/pdf/English accessed August 1st 2011) 
14. Conclusion 
The treatment landscape for metastatic RCC has dramatically changed with the 
development of targeted therapy. Metastatic RCC, once considered a dismal disease to treat 
has been transformed into a treatable cancer in the era of targeted therapy. These agents are 
now being investigated either in a sequential or combination fashion in an attempt to search 
for improved clinical efficacy. The side-effects profile is unique to each agent although there 
are some common class adverse effects. Careful monitoring and management of side-effects 
are warranted for patients on these agents to ensure good adherence and effective therapy. 
Further understanding and insight into the intracellular molecular signaling pathways to 
both clear-cell and non-clear cell RCC will hopefully lead to the discovery of agents that 
would confer more durable response and improved prognosis.  
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